Literature DB >> 20872810

Expression of B7-H4 in blood of patients with gastric cancer predicts tumor progression and prognosis.

Takaaki Arigami1, Yoshikazu Uenosono, Munetsugu Hirata, Takahiko Hagihara, Shigehiro Yanagita, Sumiya Ishigami, Shoji Natsugoe.   

Abstract

BACKGROUND AND OBJECTIVES: B7-H4 is a novel molecular B7 ligand that plays an important role as a negative regulator of the T cell-mediated immune response. However, the clinical significance of B7-H4 expression in gastric cancer remains uncertain. Here, we assessed B7-H4 expression in blood of patients with gastric cancer to determine whether or not it can predict tumor progression and prognosis.
METHODS: We measured B7-H4 mRNA expression by quantitative RT-PCR in five gastric cell lines as well as in blood specimens from 94 patients with gastric cancer and from 22 healthy volunteers.
RESULTS: Significantly more B7-H4 mRNA copies were found in gastric cell lines and in blood from patients with gastric cancer than in blood from healthy volunteers (P < 0.0001 and P < 0.0001, respectively). B7-H4 expressed in 71 (75.5%) of 94 patients with gastric cancer significantly correlated with depth of tumor invasion, lymph node metastasis, and overall stage (P = 0.006, P = 0.001, and P < 0.001, respectively). The 5-year survival rate was significantly lower in patients with than without B7-H4 expression (P = 0.04).
CONCLUSIONS: The evaluation of B7-H4 expression in blood is a useful tool for predicting the progression of gastric cancer and prognosis. 2010 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20872810     DOI: 10.1002/jso.21722

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  18 in total

1.  Detection of early-stage extrahepatic cholangiocarcinoma in patients with biliary strictures by soluble B7-H4 in the bile.

Authors:  Wenbo Ke; Li Zeng; Yunbi Hu; Sisi Chen; Min Tian; Qinggang Hu
Journal:  Am J Cancer Res       Date:  2018-04-01       Impact factor: 6.166

2.  Clinical significance of the B7-H4 coregulatory molecule as a novel prognostic marker in gastric cancer.

Authors:  Takaaki Arigami; Yoshikazu Uenosono; Sumiya Ishigami; Takahiko Hagihara; Naoto Haraguchi; Shoji Natsugoe
Journal:  World J Surg       Date:  2011-09       Impact factor: 3.352

3.  Prognostic value of soluble H7-B4 in pleural effusion associated with lung cancer.

Authors:  Chun-Hua Xu; Lan Cao; Xiu-Wei Zhang; Jun Yan; Li-Ke Yu
Journal:  Tumour Biol       Date:  2015-02-01

4.  Host b7x promotes pulmonary metastasis of breast cancer.

Authors:  Yael M Abadi; Hyungjun Jeon; Kim C Ohaegbulam; Lisa Scandiuzzi; Kaya Ghosh; Kimberly A Hofmeyer; Jun Sik Lee; Anjana Ray; Claudia Gravekamp; Xingxing Zang
Journal:  J Immunol       Date:  2013-03-01       Impact factor: 5.422

5.  The Immune Regulator VTCN1 Gene Polymorphisms and Its Impact on Susceptibility to Breast Cancer.

Authors:  Shih-Meng Tsai; Szu-Hsien Wu; Ming-Feng Hou; Hlio-Han Yang; Li-Yu Tsai
Journal:  J Clin Lab Anal       Date:  2014-11-10       Impact factor: 2.352

Review 6.  Advances in targeting cell surface signalling molecules for immune modulation.

Authors:  Sheng Yao; Yuwen Zhu; Lieping Chen
Journal:  Nat Rev Drug Discov       Date:  2013-02       Impact factor: 84.694

Review 7.  B7-H4's role "beyond the tumor".

Authors:  Ning Yu; Xiaomei Li; Songguo Zheng; Xiangpei Li
Journal:  Inflammation       Date:  2013-08       Impact factor: 4.092

Review 8.  B7 family checkpoint regulators in immune regulation and disease.

Authors:  Sabrina Ceeraz; Elizabeth C Nowak; Randolph J Noelle
Journal:  Trends Immunol       Date:  2013-08-13       Impact factor: 16.687

Review 9.  The inhibitory role of b7-h4 in antitumor immunity: association with cancer progression and survival.

Authors:  Changjun He; Haiquan Qiao; Hongchi Jiang; Xueying Sun
Journal:  Clin Dev Immunol       Date:  2011-10-13

10.  B7-H4 expression is associated with tumor progression and prognosis in patients with osteosarcoma.

Authors:  Qiang Dong; Xinlong Ma
Journal:  Biomed Res Int       Date:  2015-04-14       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.